T. Rowe Price Investment Management Inc. Purchases New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

T. Rowe Price Investment Management Inc. purchased a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 82,165 shares of the company's stock, valued at approximately $1,757,000. T. Rowe Price Investment Management Inc. owned approximately 0.55% of Jasper Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in JSPR. Rock Springs Capital Management LP raised its position in shares of Jasper Therapeutics by 0.9% in the fourth quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company's stock valued at $9,901,000 after buying an additional 4,000 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Jasper Therapeutics by 16.9% in the fourth quarter. Russell Investments Group Ltd. now owns 247,272 shares of the company's stock worth $5,287,000 after acquiring an additional 35,746 shares in the last quarter. State Street Corp boosted its position in Jasper Therapeutics by 12.3% during the 3rd quarter. State Street Corp now owns 214,883 shares of the company's stock worth $4,042,000 after purchasing an additional 23,564 shares during the period. Marshall Wace LLP grew its stake in shares of Jasper Therapeutics by 17.2% in the fourth quarter. Marshall Wace LLP now owns 77,722 shares of the company's stock valued at $1,662,000 after buying an additional 11,397 shares in the last quarter. Finally, Schroder Investment Management Group acquired a new stake in Jasper Therapeutics in the fourth quarter valued at approximately $1,237,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JSPR shares. Royal Bank of Canada lowered their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research note on Thursday, January 9th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Jasper Therapeutics in a report on Tuesday, March 11th. JMP Securities reaffirmed a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, UBS Group began coverage on Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics presently has an average rating of "Buy" and an average target price of $62.50.

Jasper Therapeutics Price Performance

JSPR traded down $0.11 on Thursday, reaching $5.38. 139,744 shares of the company traded hands, compared to its average volume of 286,388. Jasper Therapeutics, Inc. has a 52-week low of $3.13 and a 52-week high of $26.84. The stock's 50 day moving average price is $4.78 and its 200-day moving average price is $12.23. The company has a market cap of $80.82 million, a price-to-earnings ratio of -1.14 and a beta of 2.55.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). As a group, equities research analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.